Diabetes Mellitus Type II Clinical Trial
This is a multi-center, non-randomized, and interventional study in which subjects will use
the Integrated sensor and infusion set with MiniLink Transmitter and the Medtronic Paradigm®
VEO™ insulin pump (Sensor augmented pump) for 15 days.
The purpose of this study is to collect performance data on the Integrated sensor and
infusion set for approximately 15 days, with the intention for each subject to wear 5 sets
for 3 days each.
n/a
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT02261545 -
The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient
|
Phase 4 | |
| Completed |
NCT02028091 -
Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements
|
N/A | |
| Completed |
NCT01684813 -
VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel
|
Phase 4 | |
| Completed |
NCT01252524 -
Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study
|
N/A | |
| Recruiting |
NCT01311401 -
Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel
|
N/A | |
| Completed |
NCT00563225 -
20 Week Bridging Study in Type II DM
|
Phase 3 | |
| Recruiting |
NCT01565096 -
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
|
Phase 4 | |
| Completed |
NCT00151697 -
LANN-study: Lantus, Amaryl, Novorapid, Novomix Study
|
Phase 3 | |
| Withdrawn |
NCT01453751 -
Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes
|
N/A | |
| Completed |
NCT01281098 -
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.
|
Phase 2 | |
| Completed |
NCT01669473 -
A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use
|
N/A | |
| Completed |
NCT02036372 -
Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus
|
N/A | |
| Completed |
NCT03258840 -
EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus
|
N/A | |
| Active, not recruiting |
NCT01386801 -
Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana
|
N/A | |
| Completed |
NCT02144948 -
Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II
|
Phase 3 |